De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Applied DNA Sciences Beheer

Beheer criteriumcontroles 4/4

De CEO Applied DNA Sciences' is James Hayward, benoemd in Apr2006, heeft een ambtstermijn van 18.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 468.00K, bestaande uit 96.2% salaris en 3.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.066% van de aandelen van het bedrijf, ter waarde € 2.48K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.4 jaar en 8.4 jaar.

Belangrijke informatie

James Hayward

Algemeen directeur

US$468.0k

Totale compensatie

Percentage CEO-salaris	96.2%
Dienstverband CEO	18.3yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	9.4yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is James Hayward's beloning veranderd ten opzichte van Applied DNA Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$7m
Sep 30 2023	US$468k	US$450k	-US$10m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	US$2m	US$450k	-US$8m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	US$1m	US$400k	-US$14m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	US$451k	US$133k	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	US$375k	US$233k	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$481k	US$250k	-US$12m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	n/a	n/a	-US$12m
Sep 30 2017	US$546k	US$282k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 468.00K ) James } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 509.29K ).

Compensatie versus inkomsten: De vergoeding van James is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

James Hayward (70 yo)

18.3yrs

Tenure

US$468,000

Compensatie

Dr. James A. Hayward, Ph D., Sc D., has been Chief Executive Officer and Chairman of Applied DNA Sciences, Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and since June 12, 2007...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Hayward	Chairman	18.3yrs	US$468.00k	0.066% € 2.5k
Beth Jantzen	Chief Financial Officer	9.4yrs	US$501.00k	0.020% € 759.3
Judith Murrah	COO, Chief Information Officer & Secretary	11.1yrs	US$542.75k	0.023% € 865.6
Clay Shorrock	Chief Legal Officer & Executive Director of Business Development	3.3yrs	US$501.00k	0.027% € 1.0k
Sanjay Hurry	Executive Director of Investor Relations & Corporate Communications	4yrs	geen gegevens	geen gegevens

9.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van UDJ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Hayward	Chairman	18.8yrs	US$468.00k	0.066% € 2.5k
Robert Catell	Chairman of Strategic Advisory Board & Independent Director	8.4yrs	US$152.50k	0.00095% € 35.9
Yacov Shamash	Independent Director	18.3yrs	US$162.50k	0.00077% € 29.1
Raymond Kelly	Member of Strategic Advisory Board	7.5yrs	geen gegevens	geen gegevens
Joseph Ceccoli	Independent Director	9.6yrs	US$155.00k	0.00027% € 10.2
Sanford Simon	Independent Director	18.3yrs	US$151.25k	0.000040% € 1.5
Mehmood Khan	Member of Strategic Advisory Board	7.8yrs	geen gegevens	geen gegevens
Gunther Faber	Member of Strategic Advisory Board	8.4yrs	geen gegevens	geen gegevens
Elizabeth M. Shaheen	Independent Director	7.1yrs	US$153.75k	0.00038% € 14.4
Stephen Birkhold	Member of Strategic Advisory Board	5.5yrs	geen gegevens	geen gegevens

8.4yrs

Gemiddelde duur

73yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van UDJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

Applied DNA Sciences Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Insufficient new directors

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Recent updates

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

First quarter 2024 earnings released: US$0.075 loss per share (vs US$0.30 loss in 1Q 2023)

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.93 loss in FY 2022)

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.046 (vs US$0.23 loss in 2Q 2022)

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.63 loss in 1Q 2022)

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Full year 2022 earnings released: US$0.93 loss per share (vs US$2.07 loss in FY 2021)

Insufficient new directors

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.46 loss in 3Q 2021)

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2021)

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q1, 2022 Results on Feb 10, 2022

Applied DNA Sciences, Inc. to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

Applied DNA Clinical Labs Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.46 loss per share (vs US$0.72 loss in 3Q 2020)

Applied DNA Sciences and A&E Introduce Anti-Counterfeiting Technology for Sustainable Sewing Threads

Applied DNA Sciences, Inc. and Evvivax, S.R.L. Announce Results from in Vitro Neutralization Study of Sera

Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.79 loss in 2Q 2020)

Applied Dna Sciences, Inc. Clarifies the Scope of Its Newly Authorized Asymptomatic Serial Screening Indication for Its Linea Covid-19 Assay Kit

FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing

Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic Covid-19 Testing

Applied DNA and Evvivax Announce LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Applied DNA Provides Revenue Guidance for the Fiscal Second Quarter Ended March 31, 2021

Applied DNA Sciences, Inc. Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests